ACUTE MYOCARDIAL INFARCTION (AMI)

This trial investigates whether using a temporary heart pump (microaxial flow pump) right after opening a blocked artery improves survival in people with cardiogenic shock—a life-threatening condition where the heart can't pump enough blood. It also tests whether advanced monitor…

This trial tests whether giving empagliflozin before or after a procedure to open a blocked heart artery (primary PCI) reduces heart muscle injury during a heart attack. Adults aged 18-75 of South Asian origin having their first heart attack will be randomly assigned to receive e…

This study tests whether adding mobile health tools—like smartphone apps, connected scales, blood pressure monitors, and activity trackers—to standard cardiac rehab helps heart patients monitor their health and stick to healthy habits at home. The trial enrolls adults who have ha…

This trial tests whether filtering a specific inflammatory protein (C-reactive protein, or CRP) from the blood can improve outcomes in people with cardiogenic shock—a life-threatening condition where the heart cannot pump enough blood—after a heart attack. About 50 participants w…

This study tests a drug called NL005 in people who have had a severe type of heart attack (STEMI) and undergone emergency artery-opening treatment. The goal is to see if NL005 can reduce permanent heart muscle damage. Participants will receive either NL005 or a placebo daily for …

This study tests whether inserting a heart pump (IABP) early, before severe shock develops, can reduce deaths in patients who develop a hole in the heart after a heart attack. The trial will enroll 100 patients across 5 centers, randomly assigning half to receive the pump within …

This study tests a new treatment called MiSaver, made from umbilical cord blood cells, for people who recently had a heart attack. The goal is to see if it safely helps the heart pump better and reduces future heart problems. About 102 participants will either receive the cell tr…

This study tests whether starting the drug tafolecimab (a PCSK9 inhibitor) just before emergency angioplasty can lower the chance of major heart problems over the next year in people having a heart attack. About 1,160 adults will either get the drug plus standard care or standard…

This large study will test whether adding Shexiang Baoxin Pill (Muskardia) to standard treatment helps people who have had a heart attack. About 9,588 participants will receive either standard care alone or standard care plus the pill for 12 months. The goal is to see if the pill…

This study looks at whether a 12-week cardiac rehabilitation program—including supervised exercise, education, and lifestyle advice—can improve heart function and quality of life in people who have had a heart attack treated with stenting. One hundred participants will be randoml…

This study aims to create a risk prediction model for acute myocardial infarction (heart attack) using artificial intelligence and wearable devices. Researchers will enroll 3,000 high-risk patients in the Beijing area and collect data from ECGs and other sources. The goal is to e…

This study follows 600 older adults (age 60+) who have had a heart attack to see if aging-related markers in their blood and body can predict future heart problems or death. Researchers collect medical data, blood samples, and heart scans over at least two years. The goal is to b…

This study will follow 6000 people with heart disease or recent heart attacks for years. Researchers will collect blood, urine, and stool samples, plus medical data, to build a huge database. They hope artificial intelligence can find new ways to predict, diagnose, and treat hear…